Form 4: ImmuCell Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director David Scott Tomsche was granted 11,933 non-qualified stock options as compensation for board service.
Summary
- Director David Scott Tomsche received a grant of 11,933 non-qualified stock options on April 15, 2026.
- The options have an exercise price of $7.60 per share.
- The grant is intended as compensation for services provided on the ImmuCell Corporation board of directors.
- The options vest in three tranches: 3,977 shares on April 15, 2027, 3,977 shares on April 15, 2028, and 3,979 shares on April 15, 2029.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon the exercise of these options.
Risks
- The value of the options is dependent on the future market performance of ImmuCell common stock.
Future Outlook
The options vest over a three-year period, indicating a long-term retention strategy for board members.
Management Comments
- The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 11,933 stock options to Director David Scott Tomsche. | 04/15/2026 | Standard compensation practice; minimal impact on governance structure. |
Stakeholder Impact
- Shareholders may experience minor dilution if options are exercised in the future.
Next Steps
- Vesting of options beginning April 15, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/15/2026 | Date of grant for the stock options. |
| 04/16/2026 | Date the Form 4 was filed. |
| 04/15/2027 | First vesting date for the granted options. |
| 04/15/2028 | Second vesting date for the granted options. |
| 04/15/2029 | Final vesting date for the granted options. |
| 04/15/2036 | Expiration date of the stock options. |
Keywords
ImmuCell, ICCC, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.